Investor Presentation Q1 2023

80 Investor presentation First three months of 2023 Novo NordiskⓇ While NorditropinⓇ is the market leader within GHD market, SogroyaⓇ represents an opportunity for patients Novo Nordisk leadership in competitive hGH market DKK Value MS% 50% billion 20 15 10 10 34.5% 40% 30% 20% SOGROYAⓇ somapacitan • A portfolio offering across markets Sogroya® launches Once-weekly efficacious treatment on par with NorditropinⓇ Appears to have safe profile and no injection site reactions Simple and easy-to-use device Phase 3 trials toward broad range of indications (e.g. SGA, Turner, Noonan, ISS) to expand the market 5 0 Jan 2020 Segment Value Pfizer Merck Kgaa 10% 0% Dec 2022 Novo Nordisk Eli Lilly -Roche hGH: Human growth hormone; SGA: Small for gestational age, ISS; Idiopathic short stature Source: IQVIA, MAT Dec 2022; US panels for GHT has been removed from IQVIA from Jan 2022 version norditropinⓇ (somatropin) injection NorditropinⓇ strategy Apply a market-fit approach to support specific markets and patient groups Broad label across eight indications

View entire presentation